Shares of CVS Health Corp (NYSE:CVS) have earned an average rating of “Buy” from the twenty-four brokerages that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, twelve have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $86.63.
A number of equities analysts have issued reports on CVS shares. Raymond James Financial reissued a “buy” rating on shares of CVS Health in a research report on Monday, December 4th. Royal Bank of Canada set a $95.00 price target on shares of CVS Health and gave the stock a “buy” rating in a research report on Monday, December 4th. Leerink Swann set a $85.00 price target on shares of CVS Health and gave the stock a “buy” rating in a research report on Monday, December 4th. Needham & Company LLC raised their price target on shares of CVS Health from $79.00 to $85.00 and gave the stock a “buy” rating in a research report on Monday, December 4th. Finally, Deutsche Bank started coverage on shares of CVS Health in a research report on Monday, December 4th. They set a “buy” rating and a $90.00 price target for the company.
In other news, EVP Helena Foulkes sold 19,965 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $71.04, for a total transaction of $1,418,313.60. Following the sale, the executive vice president now owns 65,072 shares of the company’s stock, valued at approximately $4,622,714.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Lisa Bisaccia sold 29,445 shares of CVS Health stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the sale, the executive vice president now directly owns 15,556 shares in the company, valued at approximately $1,166,700. The disclosure for this sale can be found here. 0.61% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in CVS. Arrowstreet Capital Limited Partnership grew its stake in CVS Health by 7,225.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,871,164 shares of the pharmacy operator’s stock valued at $498,159,000 after acquiring an additional 6,777,364 shares during the period. American International Group Inc. grew its stake in CVS Health by 1,342.0% in the 4th quarter. American International Group Inc. now owns 7,081,461 shares of the pharmacy operator’s stock valued at $513,406,000 after acquiring an additional 6,590,370 shares during the period. FMR LLC grew its stake in CVS Health by 22.0% in the 2nd quarter. FMR LLC now owns 30,150,634 shares of the pharmacy operator’s stock valued at $2,425,920,000 after acquiring an additional 5,446,930 shares during the period. Truepoint Inc. grew its stake in CVS Health by 8,578.9% in the 3rd quarter. Truepoint Inc. now owns 3,757,530 shares of the pharmacy operator’s stock valued at $3,758,000 after acquiring an additional 3,714,235 shares during the period. Finally, Old Mutual Global Investors UK Ltd. acquired a new stake in CVS Health in the 4th quarter valued at $211,243,000. 83.96% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CVS Health (NYSE:CVS) traded down $1.14 during trading on Friday, hitting $62.49. 1,987,039 shares of the company traded hands, compared to its average volume of 8,740,541. The stock has a market cap of $66,604.02, a price-to-earnings ratio of 9.68, a P/E/G ratio of 1.09 and a beta of 1.03. The company has a quick ratio of 0.52, a current ratio of 1.02 and a debt-to-equity ratio of 0.59. CVS Health has a 52-week low of $62.45 and a 52-week high of $84.00.
CVS Health (NYSE:CVS) last announced its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.88 by $0.04. The firm had revenue of $48.39 billion during the quarter, compared to analyst estimates of $47.54 billion. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. CVS Health’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm posted $1.71 EPS. analysts anticipate that CVS Health will post 6.37 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 3rd. Stockholders of record on Monday, April 23rd will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, April 20th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 3.20%. CVS Health’s payout ratio is 30.91%.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.thestockobserver.com/2018/03/20/brokerages-set-cvs-health-corp-cvs-pt-at-86-63.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.